Article
RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis
24 Oct 2022
Abstract excerpt
BACKGROUND: Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC. Recent genomic studies implicated the Hippo / Yap signal is over activated in TNBC, manifesting it plays a key role in TNBC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
